Clinical Evaluation of Bass and Treble Controls for CI Subjects
CLASS
1 other identifier
interventional
34
1 country
2
Brief Summary
The clinical study is designed to evaluate the safety and effectiveness of recipient controlled Bass and Treble.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Jul 2016
Shorter than P25 for not_applicable
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
July 1, 2016
CompletedFirst Submitted
Initial submission to the registry
August 19, 2016
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 1, 2016
CompletedStudy Completion
Last participant's last visit for all outcomes
September 1, 2016
CompletedFirst Posted
Study publicly available on registry
September 21, 2016
CompletedJanuary 17, 2018
January 1, 2018
2 months
August 19, 2016
January 16, 2018
Conditions
Outcome Measures
Primary Outcomes (1)
Non-inferior speech perception with preferred Bass and Treble settings compared to the baseline Bass and Treble settings
Co-primary endpoint #1: This endpoint is to test that speech perception scores in noise with preferred Bass and Treble settings are non-inferior to the baseline settings. Subjects will be tested at visit one with their own settings (Baseline), and then again after four weeks use of the Bass and Treble feature. The speech signal will arrive from zero degrees azimuth at a level of 65 dB SPL, the noise will also arrive from zero degrees azimuth, however the noise will adapt according to subject responses. o-primary endpoint #2: This endpoint is to test that speech perception scores in quiet with preferred Bass and Treble settings are non-inferior to the baseline settings. Subjects will be tested at visit one with their own settings (Baseline), and then again after four weeks use of the Bass and Treble feature. The speech signal will arrive from zero degrees azimuth at a level of 50 dB SPL.
8 weeks
Secondary Outcomes (1)
Non-inferior sentence recognition in four-talker babble noise with Bass and Treble values set to the minimum (-6 Bass, - 6 Treble) compared to the baseline condition when the speech and noise are from the front
8 weeks
Other Outcomes (3)
Subjective daily diary data on the success of the daily Bass and Treble changes made during take-home use
8 weeks
Questionnaire data on the overall subjective ratings of the Bass and Treble controls (importance, confidence, ease and satisfaction)
8 weeks
Incidence of adverse events as well as the severity, relationship to treatment, outcome and actions taken will be listed for each subject and summarised.
8 weeks
Study Arms (1)
Bass and Treble controls
EXPERIMENTALBass and Treble controls are clinician enabled and provide the recipient with access to the adjustment of low and high frequency sound balance, known as Bass and Treble respectively.
Interventions
Bass and Treble controls are clinician enabled and provide the recipient with access to the adjustment of low and high frequency sound balance, known as Bass and Treble respectively
Eligibility Criteria
You may qualify if:
- Six years of age or older
- At least 3 months experience with the CP810, CP910 or CP920 sound processor
- At least 3 months experience with the CI24RE or CI500 series implant
- Willingness to participate in and to comply with all requirements of the protocol
You may not qualify if:
- Unrealistic expectations on the part of the subject, regarding the possible benefits, risks and limitations that are inherent to the procedure and prosthetic device
- Additional disabilities that would prevent participation in evaluations
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Cochlearlead
Study Sites (2)
Sydney Cochlear Implant Centre
Sydney, New South Wales, 2024, Australia
Cochlear Limited
Sydney, New South Wales, 2109, Australia
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Chris D Warren, Audiology
Employee
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
August 19, 2016
First Posted
September 21, 2016
Study Start
July 1, 2016
Primary Completion
September 1, 2016
Study Completion
September 1, 2016
Last Updated
January 17, 2018
Record last verified: 2018-01
Data Sharing
- IPD Sharing
- Will not share
Identifiable data will not be made available to the public. Data will be kept in a secure, locked environment and only the researchers working on the study, relevant authorities and authorised representatives will have access to it. Subject health records and any information obtained during the research project are subject to inspection (for the purpose of verifying the procedures and the data) by the Food and Drug Administration (FDA) of the United States of America, other national drug regulatory authorities and such as the Australian Government's Therapeutic Goods Administration (TGA), local Ethics Committees, and other duly authorised representatives of the Sponsor, or as required by law. Study subjects have consented to this.